| 1 |
31608549 | Basal insulin secretion capacity predicts the initial response and maximum levels of beta-hydroxybutyrate during therapy with the sodium-glucose co-transporter-2 inhibitor tofogliflozin, in relation to weight loss. | 2020 Feb |
2 |
| 2 |
32096571 | Influence of an SGLT2 inhibitor, tofogliflozin, on the resting heart rate in relation to adipose tissue insulin resistance. | 2020 Aug |
1 |
| 3 |
33063270 | Efficacy and Safety of Tofogliflozin and Ipragliflozin for Patients with Type-2 Diabetes: A Randomized Crossover Study by Flash Glucose Monitoring. | 2020 Dec |
1 |
| 4 |
29032638 | Sodium-glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline. | 2018 Jul |
2 |
| 5 |
29316197 | Tofogliflozin decreases body fat mass and improves peripheral insulin resistance. | 2018 May |
2 |
| 6 |
29316236 | Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS). | 2018 May |
1 |
| 7 |
28371205 | Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial. | 2017 Oct |
2 |
| 8 |
27738482 | Comparison of Combined Tofogliflozin and Glargine, Tofogliflozin Added to Insulin, and Insulin Dose-Increase Therapy in Uncontrolled Type 2 Diabetes. | 2016 Nov |
1 |